GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rubius Therapeutics Inc (OTCPK:RUBY) » Definitions » 5-Day RSI

Rubius Therapeutics (Rubius Therapeutics) 5-Day RSI : 96.76 (As of May. 07, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Rubius Therapeutics 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-05-07), Rubius Therapeutics's 5-Day RSI is 96.76.

The industry rank for Rubius Therapeutics's 5-Day RSI or its related term are showing as below:

RUBY's 5-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 55.97 vs RUBY: 96.76

Competitive Comparison of Rubius Therapeutics's 5-Day RSI

For the Biotechnology subindustry, Rubius Therapeutics's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rubius Therapeutics's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rubius Therapeutics's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Rubius Therapeutics's 5-Day RSI falls into.



Rubius Therapeutics  (OTCPK:RUBY) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rubius Therapeutics  (OTCPK:RUBY) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Rubius Therapeutics 5-Day RSI Related Terms

Thank you for viewing the detailed overview of Rubius Therapeutics's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Rubius Therapeutics (Rubius Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
124 Washington Street, Suite 101, Foxborough, MA, USA, 02035
Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.
Executives
Dannielle Appelhans officer: CEO and President C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Pablo J Cagnoni director, officer: Chief Executive Officer ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Laurence A. Turka officer: Chief Scientific Officer C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE MA 02139
Susanne Schaffert director C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
David R Epstein director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Maiken Keson-brookes officer: CLO & Corp. Secretary 35 OAK HILL ROAD, FAYVILLE MA 01745
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Noubar Afeyan director, 10 percent owner C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Jose Carmona officer: Chief Financial Officer C/O INNOCOLL HOLDINGS PLC, 3803 WEST CHESTER PIKE, NEWTOWN SQUARE PA 19073
Christina M. Coughlin officer: Chief Medical Officer C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE MA 02139

Rubius Therapeutics (Rubius Therapeutics) Headlines

From GuruFocus